接受奈韦拉平或依法韦伦治疗的HIV感染患者发生的皮疹

• 作 者: Hartmann M. Brust J. SchusterD. 潘敏
• 机 构: Dr. Hautklinik Universitt Heidelberg Voβ straβ e 2 69115 Heidelberg Germany,
• 出 处: 世界核心医学期刊文摘(皮肤病学分册)
• 发表日期: 2005年12期
• 关键词: 奈韦拉平 韦伦 皮疹 常见副作用 持续时间 交叉反应 水疱 HIV

Efavirenz and nevirapine are frequently used drugs in antiretroviral therapy. Rashes are common side effects of these drugs. In this study, we examined the characteristics of efavirenz- and nevirapine- associated rashes. This prospective nonrandomized multicenter study included 662 HIV- infected patients (efavirenz: 325, nevirapine: 337) to determine incidence, duration, cross- reactivity, and outcome upon reexposure. Of the treated patients, 4.5% (n=30) developed rashes (nevirapine: 2.4% and efavirenz: 6.4% ). In four patients treatment was not interrupted. Three patients were reexposed to the initial drug without any side effects. Therapy with nevirapine or efavirenz does not have to be interrupted if rashes exhibit no blistering, mucosal manifestations, or systemic signs.

Efavirenz and nevirapine are frequently used drugs in antiretroviral therapy. We study the characteristics of efavirenz- and nevirapine-associated rashes. This prospective nonrandomized multicenter study included 662 HIV-infected patients (efavirenz Of the treated patients, 4.5% (n = 30) developed rashes (nevirapine: 2.4% and efavirenz: 6.4%). In four Patients treatment was not interrupted. Three patients were reposed to the initial drug without any side effects. Therapy with nevirapine or efavirenz does not have to be interrupted if rashes exhibit no blistering, mucosal manifestations, or systemic signs.